Profile data is unavailable for this security.
About the company
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
- Revenue in USD (TTM)0.00
- Net income in USD-100.04m
- Incorporated2008
- Employees59.00
- LocationAstria Therapeutics Inc22 Boston Wharf Road, 10Th FloorBOSTON 02210United StatesUSA
- Phone+1 (617) 349-1971
- Fax+1 (617) 273-2637
- Websitehttps://astriatx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alumis Inc | 0.00 | -238.77m | 514.66m | 145.00 | -- | 1.47 | -- | -- | -4.52 | -4.52 | 0.00 | 6.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
| Monte Rosa Therapeutics Inc | 14.98m | -119.39m | 521.60m | 103.00 | -- | 2.53 | -- | 34.83 | -1.83 | -1.83 | 0.2215 | 3.35 | 0.0528 | -- | 33.69 | 112,594.00 | -42.10 | -- | -47.48 | -- | -- | -- | -797.26 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| IGM Biosciences Inc | 2.92m | -219.84m | 528.64m | 198.00 | -- | 7.08 | -- | 181.16 | -3.65 | -3.65 | 0.0484 | 1.33 | 0.0075 | -- | -- | 13,026.79 | -56.45 | -44.66 | -63.54 | -48.20 | -- | -- | -7,534.03 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Organogenesis Holdings Inc | 455.04m | -7.38m | 536.93m | 862.00 | -- | 1.92 | 57.07 | 1.18 | -0.0567 | -0.0567 | 3.43 | 2.10 | 1.00 | 4.09 | 4.78 | 527,886.30 | -1.62 | 5.46 | -1.97 | 6.90 | 75.29 | 74.94 | -1.62 | 4.81 | 2.74 | 6.56 | 0.1875 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Annexon Inc | 0.00 | -117.50m | 543.06m | 84.00 | -- | 1.63 | -- | -- | -1.04 | -1.04 | 0.00 | 3.14 | 0.00 | -- | -- | 0.00 | -40.34 | -44.06 | -43.09 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Astria Therapeutics Inc | 0.00 | -100.04m | 544.50m | 59.00 | -- | 2.29 | -- | -- | -2.09 | -2.09 | 0.00 | 6.05 | 0.00 | -- | -- | 0.00 | -36.02 | -64.48 | -37.72 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 378.42m | -2.46m | 550.50m | 267.00 | -- | -- | -- | 1.45 | -0.016 | -0.016 | 2.39 | -1.95 | 0.8284 | -- | 3.77 | 1,417,296.00 | -0.6832 | -4.54 | -1.07 | -5.20 | -- | -- | -0.8248 | -7.81 | -- | 3.88 | 2.08 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Humacyte Inc | 0.00 | -152.87m | 550.71m | 183.00 | -- | -- | -- | -- | -1.34 | -1.34 | 0.00 | -0.5317 | 0.00 | -- | -- | 0.00 | -115.74 | -- | -134.05 | -- | -- | -- | -- | -- | -- | -27.44 | -- | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Mind Medicine (MindMed) Inc | 0.00 | -97.80m | 554.39m | 57.00 | -- | 2.37 | -- | -- | -1.99 | -1.99 | 0.00 | 3.21 | 0.00 | -- | -- | 0.00 | -42.40 | -- | -49.28 | -- | -- | -- | -- | -- | -- | -- | 0.0849 | -- | -- | -- | -68.55 | -- | -- | -- |
| Grail Inc | -100.00bn | -100.00bn | 554.58m | 1.37k | -- | 0.2269 | -- | -- | -- | -- | -- | 77.93 | -- | -- | -- | -- | -- | -47.45 | -- | -48.55 | -- | -- | -- | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
| Third Harmonic Bio Inc | 0.00 | -39.20m | 561.88m | 51.00 | -- | 1.89 | -- | -- | -0.9694 | -0.9694 | 0.00 | 6.59 | 0.00 | -- | -- | 0.00 | -13.36 | -- | -13.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Chromadex Corp | 91.67m | 1.49m | 568.29m | 106.00 | 394.08 | 16.50 | 244.32 | 6.20 | 0.0189 | 0.0189 | 1.21 | 0.4521 | 1.67 | 3.05 | 23.51 | 864,792.40 | 2.70 | -42.11 | 4.08 | -65.14 | 61.45 | 59.68 | 1.62 | -30.64 | 2.35 | -- | 0.0004 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -56.83m | 575.10m | 28.00 | -- | 45.04 | -- | -- | -0.9262 | -0.9262 | 0.00 | 0.1983 | 0.00 | -- | -- | 0.00 | -102.63 | -38.31 | -199.23 | -43.34 | -- | -- | -- | -- | -- | -34.33 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Savara Inc | 0.00 | -82.94m | 576.64m | 37.00 | -- | 2.92 | -- | -- | -0.4452 | -0.4452 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -39.41 | -36.86 | -41.56 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.1175 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 14 Nov 2024 | 6.49m | 11.49% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 5.80m | 10.28% |
| RA Capital Management LPas of 30 Sep 2024 | 5.11m | 9.05% |
| Vestal Point Capital LPas of 30 Sep 2024 | 4.00m | 7.09% |
| Fairmount Funds Management LLCas of 30 Sep 2024 | 3.55m | 6.30% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.09m | 5.48% |
| Millennium Management LLCas of 28 Oct 2024 | 2.95m | 5.23% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.53m | 4.48% |
| FIAM LLCas of 30 Sep 2024 | 2.02m | 3.59% |
| Driehaus Capital Management LLCas of 30 Sep 2024 | 1.62m | 2.87% |
